CNC Stock or Molina Healthcare?

Centene (CNC) has seen a strong rebound, rising nearly 20% over the last month following a significant prior drop, suggesting potential undervaluation. However, despite this rally, Molina Healthcare (MOH) is presented as a more attractive investment opportunity, demonstrating superior financial performance with higher revenue growth (MOH LTM 16.1% vs CNC 13.0%) and better profitability (MOH LTM margin 3.8%), coupled with a comparatively lower valuation.

Analysis

Centene's stock (CNC) has demonstrated significant recent momentum, rebounding nearly 20% in the last month after a substantial drop in July 2025 that followed the withdrawal of its 2025 financial guidance. Despite this rally, a fundamental comparison suggests its competitor, Molina Healthcare (MOH), presents a more compelling investment case. Molina exhibits superior growth and profitability metrics, with Last 12 Months (LTM) revenue growth of 16.1% versus Centene's 13.0%, and a 3-year average revenue growth of 12.8% compared to CNC's 8.9%. Furthermore, Molina maintains a clear profitability advantage with an LTM margin of 3.8% and a 3-year average of 4.2%. The analysis posits that Molina also trades at a comparatively lower valuation, making it a more attractive opportunity, a view supported by the strongly positive sentiment score (0.7) for MOH versus a neutral score (0.0) for CNC. The core of the argument is that while CNC has recovered from being potentially undervalued, its recent price appreciation may have made the fundamentally stronger MOH a better relative value play in the managed healthcare sector.

Key Decisions for Investors

• Investors should consider evaluating Molina Healthcare (MOH) over Centene (CNC) due to its superior revenue growth, higher profitability, and comparatively more attractive valuation.
• Given Centene's recent 20% rally following a guidance withdrawal, existing holders may find this an opportune moment to review their position and consider rotating into fundamentally stronger peers like MOH.
• It is crucial to monitor the relative valuation between CNC and MOH, as CNC's recent surge may have fully priced in its recovery, leaving limited near-term upside compared to its competitor.
• Before initiating new positions, a deeper analysis into the specific drivers of Molina's margin outperformance and the strategic rationale behind Centene's guidance withdrawal is warranted to confirm the durability of these trends.